Equities

Nxera Pharma Co Ltd

Nxera Pharma Co Ltd

Actions
  • Price (EUR)7.35
  • Today's Change0.000 / 0.00%
  • Shares traded200.00
  • 1 Year change-23.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments49,38166,55760,173
Total Receivables, Net7,1632,5202,208
Total Inventory2,903----
Prepaid expenses------
Other current assets, total5,665865427
Total current assets65,11269,94262,808
Property, plant & equipment, net7,9003,7913,817
Goodwill, net24,62315,30615,095
Intangibles, net52,2918,5779,120
Long term investments3,2661,7376,043
Note receivable - long term------
Other long term assets4264102
Total assets157,19899,41796,985
LIABILITIES
Accounts payable112----
Accrued expenses1,084877853
Notes payable/short-term debt000
Current portion long-term debt/capital leases6,773176193
Other current liabilities, total9,2163,0396,145
Total current liabilities17,1854,0927,191
Total long term debt67,20029,55829,078
Total debt73,97329,73429,271
Deferred income tax1,4902,9222,706
Minority interest------
Other liabilities, total4,5134,909542
Total liabilities90,38841,48139,517
SHAREHOLDERS EQUITY
Common stock46,80741,33541,036
Additional paid-in capital34,04829,52529,100
Retained earnings (accumulated deficit)(16104)(8911)(9768)
Treasury stock - common(1)(1)0
Unrealized gain (loss)84(584)819
Other equity, total1,976(3428)(3719)
Total equity66,81057,93657,468
Total liabilities & shareholders' equity157,19899,41796,985
Total common shares outstanding898282
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.